Sep 2026· Journal of Alzheimer's Disease· Vol 114, pp. 938 - 952· 0 citations· 59 references
Medicine
TL;DR
The real-world diagnostic journey, barriers, and management pathways of MCI and mild AD dementia patients in Italy is characterized to characterize the real-world diagnostic journey, barriers, and management pathways of biomarker-based diagnostics in Italy.
Abstract
Background The identification and early diagnosis of mild cognitive impairment (MCI) and mild Alzheimer's disease (AD) dementia are critical for timely intervention, yet implementation of biomarker-based diagnostics in the Italian healthcare system remains limited. Objective To characterize the real-world diagnostic journey, barriers, and management pathways of MCI and mild AD dementia patients in Italy. Methods Data were drawn from the Adelphi Real World Dementia Disease Specific Programme™, a cross-sectional survey of Italian primary care physicians and specialists. Physicians reported on diagnostic assessments, biomarker testing, and treatment initiation for consulting patients with MCI/mild AD dementia. Results Physicians provided data on 325 patients (mean age: 74.1 years; 48.3% female). Patients aged ≥75 had lower Mini-Mental State Examination scores at survey (p = 0.0028) and diagnosis (p = 0.0223) than patients aged <75 years. Short-term memory loss (87.6%) was the most common symptom. Delays in diagnosis were most commonly attributed to limited specialist access (55.8%), prolonged interval between consultations (27.0%), and restricted diagnostic resources (20.4%). Magnetic resonance imaging was the primary imaging modality (65.7%), while biomarker testing such as cerebrospinal fluid and amyloid positron emission tomography were performed in 15.9% and 16.3% of cases, likely hindered by patient's reluctance and cost, respectively, as indicated by specialist-perceived challenges in using biomarkers for early symptomatic AD diagnosis. Patients whose treatment was initiated by specialists were commonly prescribed acetylcholinesterase inhibitors (72.8%). Conclusions Delays in MCI and mild AD dementia diagnosis persist alongside systemic barriers and limited biomarker use. Improving referral pathways and biomarker access is essential for timely diagnosis and management.
This pilot study demonstrates the feasibility of the PREDEM primary care study design and data collection procedures and targeted recruitment of older adults with cardiometabolic risk factors was able to identify a population relevant to the study aims.
Sandar Aye, Signe Åhrberg, Axel C. Carlsson et al.· Alzheimer's Research & Thera...· 0 citations
Episodic memory demonstrated the strongest predictive performance among the individual assessment domains evaluated of 24-month progression from MCI to AD, with functional assessment providing substantial complementary value.
BACKGROUND AND OBJECTIVES
Mild cognitive impairment (MCI), Alzheimer disease (AD), and AD-related dementias (ADRD) are growing public health concerns. Regional, demographic, and clinical differences in these diagnoses and associated comorbid conditions may inform strategies to improve prevention, care, and outcomes. To...
Sahar F. Zafar, L. Moura, Brittany Gorham et al.· Neurology Clinical Practice· 0 citations
Evidence‐based recommendations are intended to support clinicians, particularly in primary care, to identify MCI and plan an intervention strategy to help slow age‐related cognitive decline.
N. Kandiah, Y. Chan, D. Dasig et al.· CNS Neuroscience & Therapeut...· 0 citations
Apathy is a robust and consistent behavioral predictor of progression from MCI to clinical AD dementia, and domain-specific neuropsychiatric assessment may improve future risk stratification.
Yu-Ying Sun, Yu Cao, Jin-Ye Ma et al.· International Psychogeriatri...· 1 citation
YOAD remains underrecognized and diagnostically challenging, limiting timely access to targeted therapies and the integration of multimodal biomarkers and genetic testing is essential for early diagnosis, as is the need for a comprehensive neuropsychological assessment to capture atypical phenotypes.
A. Schild, C. Bartels, R. Dodel· Expert Review of Neurotherap...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.